Literature DB >> 16136507

Cox and mesothelioma: an overview.

I Cardillo1, E P Spugnini, A Verdina, R Galati, G Citro, A Baldi.   

Abstract

Cyclooxygenases catalyze the rate limiting step in the production of prostanoids. Accumulating data demonstrate that overexpression of these enzymes, and in particular of cyclooxygenases-2, promotes multiple events involved in tumorigenesis; in addition, numerous studies show that inhibition of cyclooxygenases-2 can delay or prevent certain forms of cancer. Malignant mesothelioma is a lethal pleural, peritoneal and pericardial neoplasia that actually lacks valid therapies and in which cyclooxygenases-2 is recognized as an important adverse prognostic factor. Hence, there is an increasing interest in the development of new treatments based on cyclooxygenases-2 inhibitors, to prolong survival and even potentially cure this neoplasia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136507     DOI: 10.14670/HH-20.1267

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  2 in total

1.  Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Authors:  Daniela Stoppoloni; Claudia Canino; Irene Cardillo; Alessandra Verdina; Alfonso Baldi; Ada Sacchi; Rossella Galati
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

2.  Design, Synthesis, and Evaluation of New Tripeptides as COX-2 Inhibitors.

Authors:  Ermelinda Vernieri; Isabel Gomez-Monterrey; Ciro Milite; Paolo Grieco; Simona Musella; Alessia Bertamino; Ilaria Scognamiglio; Stefano Alcaro; Anna Artese; Francesco Ortuso; Ettore Novellino; Marina Sala; Pietro Campiglia
Journal:  J Amino Acids       Date:  2013-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.